Loading organizations...
§ Private Profile · Ghent, Belgium
Biotech company developing next-generation immune modulators for autoimmune diseases, focused on Treg therapies.
dualyx has raised $43.5M across 1 funding round.
Key people at dualyx.
dualyx has raised $43.5M in total across 1 funding round.
Dualyx is a Ghent, Belgium-based biotechnology company that develops next-generation immune modulators using llama-derived antibodies to selectively expand regulatory T cells for the treatment of autoimmune diseases. The organization's lead preclinical program, DT-001, functions as an agonist targeting the TNF receptor 2 to restore immune balance, supported by a pipeline of additional early-stage therapies. The clinical-stage biotechnology enterprise operates with a workforce of more than 50 employees and has secured approximately $52.89 million in total funding, which includes a $44 million Series A round and a €7 million seed round. This recent equity financing was co-led by prominent venture capital firms Forbion, Fountain Healthcare Partners, and Andera Partners, while the company also maintains strategic research collaborations with Argenx and Ghent University. Dualyx was originally founded in 2020 by chief scientific officer Luc Van Rompaey.
dualyx has raised $43.5M across 1 funding round. Most recently, it raised $43.5M Series A in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 15, 2023 | $43.5M Series A | Aneta Sottil, Juliette Audet, ENA Prosser | Benhamou Global Ventures, GFF, High Tech Grunderfonds, PMV, V BIO Ventures, VIB | Announced |
Key people at dualyx.
Dualyx is a Ghent, Belgium-based biotech company developing next-generation immune modulators, primarily novel Treg-based therapies targeting autoimmune diseases.[1][2][3] Its lead program, DT-001, is an antibody agonist for TNF receptor 2 (TNFR2), which selectively expands regulatory T cells (Tregs) to suppress immune overactivity, with additional preclinical pipeline candidates like DT-002 and DT-003.[3][4][7] Dualyx serves patients with hard-to-treat autoimmune disorders, addressing unmet needs in immune modulation by progressing therapies from preclinical stages toward clinical proof-of-concept.[2][3] In May 2023, it raised €40 million ($44 million) in a Series A round co-led by Forbion, Andera Partners, and Fountain Healthcare Partners, supported by existing investors including BGV, V-Bio Ventures, PMV, VIB, HTGF, and GFF, following a €7 million seed round; funds support IND-enabling studies for DT-001 and pipeline expansion.[2][3][4]
Dualyx was founded in 2021 by CSO Luc Van Rompaey through a collaborative model involving Wurzburg University, argenx, VIB, Ghent University, and KU Leuven.[2][4] The idea emerged from expertise in antibody technology and Treg biology, focusing on TNFR2 as a "master control switch" for immune suppression.[2][3][4] Early traction came via a €7 million seed round from European life sciences investors, enabling preclinical validation of DT-001's selective Treg expansion across species.[2][4] Leadership includes CEO Wouter Verhoeven, with recent additions like Independent Chairman Bernard Coulie (CEO of Pliant Therapeutics) and board members Juliette Audet (Forbion) and Aneta Sottil (Andera Partners).[2][3][4]
Dualyx rides the surging wave of Treg-focused immunomodulation in autoimmune diseases, a trend fueled by limitations of existing therapies like JAK inhibitors and anti-TNFs, which often lack selectivity and long-term efficacy.[2][3] Timing aligns with advances in antibody engineering and growing recognition of TNFR2 as a key Treg regulator, amid a booming biotech investment in precision immunology post-2020s funding resurgence.[2][4] Market forces favoring Dualyx include rising autoimmune prevalence (e.g., rheumatoid arthritis, IBD), regulatory emphasis on novel mechanisms, and Europe's strong life sciences ecosystem in Belgium/Netherlands/Germany.[1][2] It influences the ecosystem by validating academic-industry collaborations and drawing capital to Treg assets, potentially accelerating competitors and setting benchmarks for preclinical-to-clinical transitions.[2][4]
Dualyx is poised to advance DT-001 into IND submission and early clinical trials within 1-2 years, leveraging Series A funds for proof-of-concept data that could validate TNFR2 agonists and unlock follow-on financing.[3][4] Key trends shaping its path include AI-driven antibody optimization, combination therapies with checkpoint inhibitors, and expanding autoimmune indications amid a projected $150B+ market.[7] Its influence may grow through partnerships or acquisitions by big pharma seeking next-gen immunology, evolving from preclinical innovator to clinical leader—building on its strong 2023 funding momentum to tackle unmet needs in immune diseases.[2][3]
dualyx has raised $43.5M in total across 1 funding round.
dualyx's investors include Aneta Sottil, Juliette Audet, Ena Prosser, Benhamou Global Ventures, GFF, High-Tech Grunderfonds, PMV, V-Bio Ventures, VIB.
